COUNTERPOINT: Should Therapeutic Heparin Be Administered to Acutely Ill Hospitalized Patients With COVID-19? No

Detalles Bibliográficos
Autores principales: Jimenez, David, Rali, Parth, Doerschug, Kevin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Inc under license from the American College of Chest Physicians. 2022
Materias:
Editorial: Point and Counterpoint
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8923523/
https://www.ncbi.nlm.nih.gov/pubmed/35550714
http://dx.doi.org/10.1016/j.chest.2022.01.037
_version_ 1784669692620701696
author Jimenez, David
Rali, Parth
Doerschug, Kevin
author_facet Jimenez, David
Rali, Parth
Doerschug, Kevin
author_sort Jimenez, David
collection PubMed
description
format Online
Article
Text
id pubmed-8923523
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Published by Elsevier Inc under license from the American College of Chest Physicians.
record_format MEDLINE/PubMed
spelling pubmed-89235232022-03-15 COUNTERPOINT: Should Therapeutic Heparin Be Administered to Acutely Ill Hospitalized Patients With COVID-19? No Jimenez, David Rali, Parth Doerschug, Kevin Chest Editorial: Point and Counterpoint Published by Elsevier Inc under license from the American College of Chest Physicians. 2022-06 2022-03-15 /pmc/articles/PMC8923523/ /pubmed/35550714 http://dx.doi.org/10.1016/j.chest.2022.01.037 Text en © 2022 Published by Elsevier Inc under license from the American College of Chest Physicians. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Editorial: Point and Counterpoint
Jimenez, David
Rali, Parth
Doerschug, Kevin
COUNTERPOINT: Should Therapeutic Heparin Be Administered to Acutely Ill Hospitalized Patients With COVID-19? No
title COUNTERPOINT: Should Therapeutic Heparin Be Administered to Acutely Ill Hospitalized Patients With COVID-19? No
title_full COUNTERPOINT: Should Therapeutic Heparin Be Administered to Acutely Ill Hospitalized Patients With COVID-19? No
title_fullStr COUNTERPOINT: Should Therapeutic Heparin Be Administered to Acutely Ill Hospitalized Patients With COVID-19? No
title_full_unstemmed COUNTERPOINT: Should Therapeutic Heparin Be Administered to Acutely Ill Hospitalized Patients With COVID-19? No
title_short COUNTERPOINT: Should Therapeutic Heparin Be Administered to Acutely Ill Hospitalized Patients With COVID-19? No
title_sort counterpoint: should therapeutic heparin be administered to acutely ill hospitalized patients with covid-19? no
topic Editorial: Point and Counterpoint
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8923523/
https://www.ncbi.nlm.nih.gov/pubmed/35550714
http://dx.doi.org/10.1016/j.chest.2022.01.037
work_keys_str_mv AT jimenezdavid counterpointshouldtherapeuticheparinbeadministeredtoacutelyillhospitalizedpatientswithcovid19no
AT raliparth counterpointshouldtherapeuticheparinbeadministeredtoacutelyillhospitalizedpatientswithcovid19no
AT doerschugkevin counterpointshouldtherapeuticheparinbeadministeredtoacutelyillhospitalizedpatientswithcovid19no

Ejemplares similares